Details
Stereochemistry | RACEMIC |
Molecular Formula | C10H15NO |
Molecular Weight | 165.2322 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN[C@H](C)[C@@H](O)C1=CC=CC=C1
InChI
InChIKey=KWGRBVOPPLSCSI-PSASIEDQSA-N
InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10-/m1/s1
Molecular Formula | C10H15NO |
Molecular Weight | 165.2322 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Racephedrine in combination with theophylline, phenobarbital was used to treat bronchial asthma. However, its application was substituted more effective agent. In addition, FDA has reviewed the final monograph for over-the-counter bronchodilator drug products to add additional warnings and to revise the indications in the labeling of products containing racephedrine hydrochloride.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5744603 |
Palliative | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
79.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/973934/ |
22 mg single, oral dose: 22 mg route of administration: Oral experiment type: SINGLE co-administered: |
EPHEDRINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
751 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/973934/ |
22 mg single, oral dose: 22 mg route of administration: Oral experiment type: SINGLE co-administered: |
EPHEDRINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.75 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/973934/ |
22 mg single, oral dose: 22 mg route of administration: Oral experiment type: SINGLE co-administered: |
EPHEDRINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
A racephedrine-phenyltoloxamine-containing compound (Ephoxamine) in the treatment of bronchial asthma. | 1961 Jul |
|
Labeling for bronchodilators to treat asthma; cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. Final rule. | 2011 Jul 26 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18146174
Unknown
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:23:27 GMT 2023
by
admin
on
Sat Dec 16 16:23:27 GMT 2023
|
Record UNII |
03VRY66076
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29709
Created by
admin on Sat Dec 16 16:23:28 GMT 2023 , Edited by admin on Sat Dec 16 16:23:28 GMT 2023
|
||
|
CFR |
21 CFR 119.1
Created by
admin on Sat Dec 16 16:23:28 GMT 2023 , Edited by admin on Sat Dec 16 16:23:28 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB10237MIG
Created by
admin on Sat Dec 16 16:23:28 GMT 2023 , Edited by admin on Sat Dec 16 16:23:28 GMT 2023
|
PRIMARY | |||
|
DB14752
Created by
admin on Sat Dec 16 16:23:28 GMT 2023 , Edited by admin on Sat Dec 16 16:23:28 GMT 2023
|
PRIMARY | |||
|
202-017-0
Created by
admin on Sat Dec 16 16:23:28 GMT 2023 , Edited by admin on Sat Dec 16 16:23:28 GMT 2023
|
PRIMARY | |||
|
DTXSID60889333
Created by
admin on Sat Dec 16 16:23:28 GMT 2023 , Edited by admin on Sat Dec 16 16:23:28 GMT 2023
|
PRIMARY | |||
|
m4933
Created by
admin on Sat Dec 16 16:23:28 GMT 2023 , Edited by admin on Sat Dec 16 16:23:28 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000080308
Created by
admin on Sat Dec 16 16:23:28 GMT 2023 , Edited by admin on Sat Dec 16 16:23:28 GMT 2023
|
PRIMARY | |||
|
9457
Created by
admin on Sat Dec 16 16:23:28 GMT 2023 , Edited by admin on Sat Dec 16 16:23:28 GMT 2023
|
PRIMARY | |||
|
03VRY66076
Created by
admin on Sat Dec 16 16:23:28 GMT 2023 , Edited by admin on Sat Dec 16 16:23:28 GMT 2023
|
PRIMARY | |||
|
C81363
Created by
admin on Sat Dec 16 16:23:28 GMT 2023 , Edited by admin on Sat Dec 16 16:23:28 GMT 2023
|
PRIMARY | |||
|
90-81-3
Created by
admin on Sat Dec 16 16:23:28 GMT 2023 , Edited by admin on Sat Dec 16 16:23:28 GMT 2023
|
PRIMARY | |||
|
6626
Created by
admin on Sat Dec 16 16:23:28 GMT 2023 , Edited by admin on Sat Dec 16 16:23:28 GMT 2023
|
PRIMARY | |||
|
CHEMBL2110656
Created by
admin on Sat Dec 16 16:23:28 GMT 2023 , Edited by admin on Sat Dec 16 16:23:28 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
DIASTEREOISOMER -> DIASTEREOISOMER |
|
||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |